Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF®-treated patients
- 29 January 2016
- journal article
- Published by Wiley in Haemophilia
- Vol. 22 (2), e101-e103
- https://doi.org/10.1111/hae.12867
Abstract
No abstract availableFunding Information
- Pfizer